findmyKOL
Clinical trialNCT04582669TerminatedPhase 4Interventional

Optimizing Intralesional Triamcinolone Dosing for Hidradenitis Suppurativa

SponsorMontefiore Medical CenterEnrollment11Hidradenitis Suppurativa
View the registry record on ClinicalTrials.gov

Summary

The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

  • Steven R Cohen, MD, MPH

    Albert Einstein College of Medicine Montefiore Medical Center

    Principal Investigator

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • Steven Cohen

    The Bronx, New York, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
24 Jan 2022
Primary completion
12 Oct 2022
Completion
12 Oct 2022
Last update posted
13 Nov 2023
Registered enrollment
11
Registry id
NCT04582669

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.